Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01880788|
Recruitment Status : Completed
First Posted : June 19, 2013
Last Update Posted : September 18, 2015
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.
|Condition or disease|
|Age Related Macular Degeneration Choroidal Neovascularization Central Serous Chorioretinopathy|
|Study Type :||Observational|
|Actual Enrollment :||152 participants|
|Observational Model:||Case Control|
|Official Title:||Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||August 2015|
|CNV secondary to CSC|
|CSC without CNV|
|CNV secondary to advanced AMD|
- Total genetic burden [ Time Frame: Baseline assessment ]The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01880788
|United States, New York|
|Vitreous Retina Macula Consultants of New York|
|New York City, New York, United States, 10022|